Scinai Immunotherapeutics (SCNI) Free Cash Flow (2018 - 2026)

Scinai Immunotherapeutics has reported Free Cash Flow for 9 years, with the latest figure at -$1.5 million in Q1 2026.

• Quarterly Free Cash Flow fell 40.79% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (up 32.14% YoY) and the FY2025 annual result came in at -$6.1 million, up 4.6% from the prior year.
• Free Cash Flow rose to -$1.5 million in Q1 2026 per SCNI's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.0 million in Q1 2025 and troughed at -$3.6 million in Q2 2022.
• A 5-year average of -$2.0 million and a median of -$1.8 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow soared 70.53% in 2022, then sank 87.76% in 2023.
• Over 5 years, Free Cash Flow stood at -$2.0 million in 2022, then retreated by 13.53% to -$2.3 million in 2023, then jumped by 51.43% to -$1.1 million in 2024, then tumbled by 39.18% to -$1.5 million in 2025, then grew by 5.09% to -$1.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$1.5 million, -$1.5 million, and -$1.0 million for Q1 2026, Q2 2025, and Q1 2025 respectively.